NEUROENDOCRINE TUMORS A021602
Study #A021602Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus
Back To Clinical Trials
Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus
Back To Clinical Trials